Enhance Recovery. Optimize ICU Resource Utilization.
See how PleuraFlow® Active Clearance Technology® can help free ICU resources and get patients home faster.
Read more

About Us

We believe that there is nothing more beautiful than getting patients back home to their lives and their loved ones faster.

Recovery is Beautiful®

The Team

Leadership

Paul Molloy

CEO

Paul is a serial entrepreneur and medical device industry veteran with twenty-five years experience of leading public, private and VC-funded healthcare companies. He has served on the Board and Audit Committee at CAS Medical (NASDAQ, CASM) prior to its acquisition by Edwards and on the Board at Revolutionary Medical Devices prior to its acquisition by Vyair. He currently serves on the Board at Inscope Inc. and is an advisor to several Silicon Valley technology firms. Previously, he was a Board member at MiCardia, LMA and VasoNova.

Before joining ClearFlow, Paul was CEO at VasoNova Inc., a Silicon Valley based, venture-funded vascular navigation company acquired by Teleflex Inc. (NYSE, TFX), in January 2011. Following the acquisition, he was appointed President of Teleflex’ largest division – ARROW Vascular – having full P&L responsibilities for direct sales, US and overseas manufacturing plants, R&D and strategic planning at corporate level. Under his tenure VasoNova was successfully integrated under the ARROW Vascular brand. Prior to VasoNova, Paul was President and Managing Director of LMA, overseeing all European and Asian subsidiaries. Paul took LMA public in 2005 and later brokered its acquisition by Teleflex in 2012.

Paul started his career as a practicing CRNA (Certified Registered Nurse Anesthetist) at Medical University Alkmaar in the Netherlands. In 1989 he joined Datascope Corp. where he progressed through successive corporate roles with growing responsibilities. He has extensive global industry connections and is well-versed in setting up and managing international operations. He has traveled, lived and worked in Europe, Asia and the USA and is fluent in German, Dutch and English. Paul holds an MBA from the University of Chicago’s Booth School of Business.

Ed Boyle

Founder and Chairman

Dr. Boyle is a Cardiovascular and Thoracic Surgeon in Bend, Oregon whose career spans clinical surgery, cardiovascular research, and medical innovation. He studied medicine at University of Minnesota Medical School, and trained in general surgery and cardiothoracic surgery at the University of Washington.

During his clinical training at the University of Washington, he helped lead the Cardiovascular Vascular Biology research team where he developed basic science and clinical research programs, primarily focusing on the study of tissue injury, coagulation and inflammation. Dr. Boyle has published over 75 manuscripts in peer reviewed medical journals and textbooks. In addition to obtaining NIH funding, he played a lead role in developing research collaborations with Bayer’s Pharmaceutical Division, Genentech, Zymogenetics/Novo Nordisk, Icos Corporation, US Surgical Corporation (now Covidien) and other privately held biotechnology and device companies. His research has been recognized nationally with awards from the American College of Surgeons, the American Heart Association, The Western Thoracic Surgery Association, the Seattle Surgical Society and others.

Dr. Boyle was a founder of Elixis, a healthcare information technology company which was acquired by Data Critical Corporation (NASDAQ: DCCA), now a division of General Electric (NYSE: GE). Dr. Boyle is the founder of MDI, VenX, and Precision Thoracic Corporation, all early stage medical device companies where he is an inventor on a number of medical devices patent applications.

Serrah Namini

Vice President RA, CA, QA

Serrah’s extensive experience includes ten years with the FDA as Consumer Safety Officer and Pacific Region Team Leader for Radiological Health team as well as four years working with Notified Bodies including Intertek. She has led global regulatory and quality departments and consulted for FDA regulated companies including startup, medium and large multi-site companies such as: USMC (orthopedics and prosthetics), Rhythm Technologies (electrophysiology PMA devices), Applied Medical (surgical devices), Nihon Kohden (patient monitors, EEG, EKG, EMG devices) and Karl Storz (surgical devices/monitors and endoscopes). She has prepared and submitted numerous successful 510(k)s for class II and III medical devices including implantable, electronics, software, lasers, electro-mechanical, surgical, and sterile. She has also setup Quality Assurance programs with validation processes to meet domestic and international standards/regulations including MDSAP requirements.

Her experience along with her education in Biomedical and Electrical Engineering provides a unique opportunity for ClearFlow to expand its domestic and international presence.

James Herlofsky

Director of Clinical Training

James Herlofsky, M.D. is a medical professional who brings a unique perspective to medical device education. He received his Bachelor of Science degree in Psychology from Loyola Marymount University in Los Angeles, California, before earning his M.D. from a U.S. accredited medical school in San Jose, Costa Rica. After returning to his hometown of Los Angeles, James served as the Practice Manager for a thriving West L.A.-based private medical practice, while simultaneously holding the position of administrator for an ambulatory surgical center. James speaks fluent Spanish in addition to his native English, which has allowed him to lead a number of international clinical and sales training sessions. James’ marketing and clinical background, along with his medical practice management experience, have provided him with an extensive variety of viewpoints within the healthcare industry, resulting in the unique perspective he brings to his role as Director of Clinical Education.

Tony Mathiason

U.S. Sales Director

Tony brings over 25 years of medical sales experience, the last 18 in the Cardiovascular space, with a specific emphasis on new, emerging technologies. Prior to joining ClearFlow in 2015, Tony held Regional and Territory Sales Manager positions at n-Contact, On-X Life Technologies, AtriCure and U.S. Surgical. Tony has demonstrated consistent success working in the start-up environment, and brings a breadth of knowledge on how to move a product from infancy of use to broad market acceptance. Tony has spent his entire medical sales career in Houston, Texas and holds a Bachelors of Arts Degree from the University of Houston.

Ken Chesnin

Director of R&D and Engineering

Ken is responsible for product development, engineering and IP management. He has 14 years of experience in product development and design of medical devices. Most recently he was Director of Sensor Development at GluMetrics, Inc., a venture backed company that developed a novel blood–based sensor for real-time measurement of glucose. Previously he led an engineering team at Medical Components (Medcomp) that developed and commercialized numerous FDA class II and III vascular devices. He was also Principal Engineer at Martech Medical, where he worked with startups and Fortune 500 companies to manufacture numerous medical devices and components. His experience spans idea generation, prototyping, manufacturing, design validation and process validation. He is an inventor on eight issued US utility patents and numerous design patents. Prior to his career in device development, he conducted biomechanics research at Thomas Jefferson University where he developed models for analyzing human movement. He holds a MS degree in Biomedical Engineering from Drexel University and a BS in Mechanical Engineering from State University of NY at Buffalo.

Hannah Beathard

Director of Finance

As Director of Finance, Hannah oversees all accounting and finance functions. Hannah is a Certified Public Accountant with a background in the assurance practice at PricewaterhouseCoopers. During her tenure with PricewaterhouseCoopers, Hannah played a key role in developing processes and strategies to have effective and efficient audit engagements. Hannah worked directly with firm partners and audit clients to plan and execute quarterly reviews and year-end audits in conjunction with year-round SEC filings (10-Q and 10-K) and government compliance audit deliverables. There she gained extensive experience auditing a wide array of industries ranging from healthcare to large cap manufacturing companies, both private and multinational publicly traded companies. She earned her bachelor’s degree in Accounting and Finance from the University of Delaware and is a member of the American Institute of CPAs. Hannah has remained consistently involved in the community, most recently serving as Treasurer on the Board of Girls on the Run – San Diego and as a volunteer mentor for Junior Achievement, educating youth in low income areas on financial literacy and fiscal responsibility.

Board of Directors

Ed Boyle

Founder and Chairman

Dr. Boyle is a Cardiovascular and Thoracic Surgeon in Bend, Oregon whose career spans clinical surgery, cardiovascular research, and medical innovation. He studied medicine at University of Minnesota Medical School, and trained in general surgery and cardiothoracic surgery at the University of Washington.

During his clinical training at the University of Washington, he helped lead the Cardiovascular Vascular Biology research team where he developed basic science and clinical research programs, primarily focusing on the study of tissue injury, coagulation and inflammation. Dr. Boyle has published over 75 manuscripts in peer reviewed medical journals and textbooks. In addition to obtaining NIH funding, he played a lead role in developing research collaborations with Bayer’s Pharmaceutical Division, Genentech, Zymogenetics/Novo Nordisk, Icos Corporation, US Surgical Corporation (now Covidien) and other privately held biotechnology and device companies. His research has been recognized nationally with awards from the American College of Surgeons, the American Heart Association, The Western Thoracic Surgery Association, the Seattle Surgical Society and others.

Dr. Boyle was a founder of Elixis, a healthcare information technology company which was acquired by Data Critical Corporation (NASDAQ: DCCA), now a division of General Electric (NYSE: GE). Dr. Boyle is the founder of MDI, VenX, and Precision Thoracic Corporation, all early stage medical device companies where he is an inventor on a number of medical devices patent applications.

Paul Molloy

CEO

Paul is a serial entrepreneur and medical device industry veteran with twenty-five years experience of leading public, private and VC-funded healthcare companies. He has served on the Board and Audit Committee at CAS Medical (NASDAQ, CASM) prior to its acquisition by Edwards and on the Board at Revolutionary Medical Devices prior to its acquisition by Vyair. He currently serves on the Board at Inscope Inc. and is an advisor to several Silicon Valley technology firms. Previously, he was a Board member at MiCardia, LMA and VasoNova.

Before joining ClearFlow, Paul was CEO at VasoNova Inc., a Silicon Valley based, venture-funded vascular navigation company acquired by Teleflex Inc. (NYSE, TFX), in January 2011. Following the acquisition, he was appointed President of Teleflex’ largest division – ARROW Vascular – having full P&L responsibilities for direct sales, US and overseas manufacturing plants, R&D and strategic planning at corporate level. Under his tenure VasoNova was successfully integrated under the ARROW Vascular brand. Prior to VasoNova, Paul was President and Managing Director of LMA, overseeing all European and Asian subsidiaries. Paul took LMA public in 2005 and later brokered its acquisition by Teleflex in 2012.

Paul started his career as a practicing CRNA (Certified Registered Nurse Anesthetist) at Medical University Alkmaar in the Netherlands. In 1989 he joined Datascope Corp. where he progressed through successive corporate roles with growing responsibilities. He has extensive global industry connections and is well-versed in setting up and managing international operations. He has traveled, lived and worked in Europe, Asia and the USA and is fluent in German, Dutch and English. Paul holds an MBA from the University of Chicago’s Booth School of Business.

Alexander Suh

Founding Managing Director, California Technology Ventures

Alex Suh is a founding Managing Director with California Technology Ventures, LLC, a Southern California venture capital firm that focuses its investments in the fields of Life Sciences and Information Technology.

Alex is also a founding Managing Director with J.J. Jacobs Enterprises, LLC and Jacobs Capital Group, LLC, both Pasadena-based venture capital and fund-of-fund firms where he has invested in other venture capital funds globally that offer a strategic fit with California Technology Ventures.

Alex was an entrepreneur starting several businesses, helped develop the first small business incubator in the San Gabriel Valley, managed several small business lending programs, consulted with nonprofits and cities on economic development projects and taught college in entrepreneurship, business and management.

Alex currently or formerly sat on the advisory board for EmTek, a San Diego based community small business lending and equity program; LARTA, a technology think tank; Claremont Graduate University’s Venture Financial Institute; and the Life Science Steering committee for State of California Governor’s Policy Office, Advisory Board member City of Hope’s International Translational & Regenerative Medicine Center (ITRC), SoCalBio (SCBC) Advisory Board member, and Member of Board of Trustees and Advisory Council member for Keck Graduate Institute of Applied Life Sciences.

His community involvement included past chairman to Villa Esperanza, a school for developmentally challenged persons; distinguished president for Kiwanis; Advisory board member for Women at Work and the Crippled Children’s Society; Special Olympics coach, ocean advocate and others.

Alex was honored in 2009, Outstanding 50 Asian Americans in Business while California Technology Ventures was also named by ACQ Finance Magazine’s Technology Investor of the Year, North America, 2010.

Ned Scheetz

Managing Director, Aphelion Capital

Mr. Scheetz founded Aphelion Capital, LLC in 2005. Prior to forming Aphelion, Mr. Scheetz was a partner and managing director with Piper Jaffray Ventures (PJV) for nearly eight years, focusing on investments in emerging medical technology companies. Mr. Scheetz joined PJV from Janus Capital, where he was a senior research analyst covering medical technology. Before beginning his investment career Mr. Scheetz worked in various product management roles with a subsidiary of Eastman Kodak and in sales with Kraft General Foods.

Mr. Scheetz is a graduate of Colby College, Duke University’s Fuqua School of Business, and was a post-graduate scholar at Oxford University. Mr. Scheetz holds the CFA designation, and is a board member of ClearFlow, Curant, and OrthAlign. Mr. Scheetz is an advisory board member with the Center for Medical Device Innovation, and on the business advisory board of The Epilepsy Therapy Development Project.

Chris Martin

President, Medical Devices & Chief Financial Officer, Research Corporation Technologies

Along with his responsibilities as CFO, Martin is President, Medical Devices, treasurer and a director of the RCT board of directors. He leads the RCT team focused on medical device investments. Martin holds an M.B.A. in finance/strategy from The Anderson School, UCLA, an M.S. in biomedical engineering from the University of Southern California, and a B.S. in biology/biochemistry from the University of Michigan.